CN114206344A - 包含前列腺素类似物的局部组合物 - Google Patents

包含前列腺素类似物的局部组合物 Download PDF

Info

Publication number
CN114206344A
CN114206344A CN202080055661.8A CN202080055661A CN114206344A CN 114206344 A CN114206344 A CN 114206344A CN 202080055661 A CN202080055661 A CN 202080055661A CN 114206344 A CN114206344 A CN 114206344A
Authority
CN
China
Prior art keywords
composition
use according
latanoprost
hair
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080055661.8A
Other languages
English (en)
Chinese (zh)
Inventor
F·勒舍尔
B·豪普特梅尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Demalik Therapy
Original Assignee
Novaliq GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq GmbH filed Critical Novaliq GmbH
Publication of CN114206344A publication Critical patent/CN114206344A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080055661.8A 2019-08-09 2020-08-06 包含前列腺素类似物的局部组合物 Pending CN114206344A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19191035.5 2019-08-09
EP19191035 2019-08-09
PCT/EP2020/072211 WO2021028328A1 (en) 2019-08-09 2020-08-06 Topical composition comprising a prostaglandin analogue

Publications (1)

Publication Number Publication Date
CN114206344A true CN114206344A (zh) 2022-03-18

Family

ID=67587648

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080055661.8A Pending CN114206344A (zh) 2019-08-09 2020-08-06 包含前列腺素类似物的局部组合物

Country Status (8)

Country Link
US (2) US20220362382A1 (cg-RX-API-DMAC10.html)
EP (1) EP4009952A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022543402A (cg-RX-API-DMAC10.html)
KR (2) KR20220044739A (cg-RX-API-DMAC10.html)
CN (1) CN114206344A (cg-RX-API-DMAC10.html)
AU (2) AU2020330424A1 (cg-RX-API-DMAC10.html)
CA (1) CA3144193A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021028328A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6039145B2 (ja) 2011-05-25 2016-12-07 ノバリック ゲーエムベーハー 半フッ化アルカンを基礎にした局所薬学的組成物
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
MX381639B (es) 2016-12-23 2025-03-13 Novaliq Gmbh Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
AU2019246035B2 (en) 2018-03-28 2024-07-18 Novaliq Gmbh Pharmaceutical composition comprising timolol
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
CN114449999A (zh) 2019-09-06 2022-05-06 诺瓦利克有限责任公司 用于治疗葡萄膜炎的眼用组合物
IL330080A (en) 2023-12-19 2026-08-01 Glenmark Specialty S A A preparation for external use containing dutasteride and lanotrost for the treatment of alopecia
AU2025207999A1 (en) * 2024-01-11 2026-07-23 Glenmark Specialty S.A. Topical composition comprising clascoterone and latanoprost for alopecia
WO2026013128A1 (en) * 2024-07-10 2026-01-15 Dermaliq Therapeutics, Inc. Treatment of androgenetic alopecia
WO2026104414A1 (en) * 2024-11-12 2026-05-21 Dermaliq Therapeutics Gmbh Topical compositions for the treatment of alopecia areata

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69823852T2 (de) 1997-02-04 2005-05-19 Johnstone, Murray A., Seattle Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
JP2005225817A (ja) * 2004-02-13 2005-08-25 Jiyugaoka Clinic 睫毛用育毛剤
US9149484B2 (en) * 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
NZ716349A (en) * 2009-11-09 2017-07-28 Allergan Inc Compositions and methods for stimulating hair growth
ES2564502T3 (es) * 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
CN103561724B (zh) * 2011-05-25 2016-06-29 诺瓦利克有限责任公司 给药给甲的药物组合物
AU2013208002B2 (en) 2012-01-10 2017-11-30 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
EP2944324A1 (de) * 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
DK3442480T3 (da) * 2016-06-23 2020-01-13 Novaliq Gmbh Fremgangsmåde til topisk indgivelse
JP7814839B2 (ja) * 2017-09-27 2026-02-17 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物

Also Published As

Publication number Publication date
AU2026202586A1 (en) 2026-04-23
JP2022543402A (ja) 2022-10-12
WO2021028328A1 (en) 2021-02-18
AU2020330424A1 (en) 2022-03-03
CA3144193A1 (en) 2021-02-18
EP4009952A1 (en) 2022-06-15
US20220362382A1 (en) 2022-11-17
KR20220044739A (ko) 2022-04-11
JP2025160428A (ja) 2025-10-22
KR20260055529A (ko) 2026-04-23
US20260041773A1 (en) 2026-02-12

Similar Documents

Publication Publication Date Title
US20260041773A1 (en) Topical composition comprising a prostaglandin analogue
US20240189324A1 (en) High concentration formulation
RU2567792C2 (ru) Композиции и способы стимулирования роста волос
US9149484B2 (en) Compositions and methods for stimulating hair growth
JP6082158B2 (ja) ビマトプロストを含む局所用組成物及びそれを用いた育毛の刺激方法
EP3886799B1 (en) Compositions for the treatment of hair loss
TW202444338A (zh) 克拉司酮與米諾地爾之組合療法
EP4487852A1 (en) Transdermal dosage form, for promoting local blood flow, of dual-acting pde5 inhibitor/organic nitrate ester
CN114025768B (zh) 促进毛发生长的药品
AU2016427261A1 (en) Pharmaceutical compositions
WO2026013128A1 (en) Treatment of androgenetic alopecia
WO2025069091A1 (en) Novel topical pharmaceutical composition for prevention and treatment of hair loss
WO2026057588A1 (en) Clascoterone and minoxidil combination therapy for use in treating hair loss
WO2025172818A1 (en) Pyrilutamide combination therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right

Effective date of registration: 20220729

Address after: Delaware

Applicant after: Demalik therapy

Address before: Heidelberg, Germany

Applicant before: NOVALIQ GmbH

TA01 Transfer of patent application right
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination